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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.10.002Objectives: Left ventricular assist devices are proposed as a bridge to recovery, but
recurrent ventricular deterioration has limited this approach. We describe a new
animal model that simulates the effects of left ventricular assist device unloading
and then reloading after device removal. The model might facilitate the evaluation
of interventions intended to prevent recurrent ventricular dysfunction.
Methods: The hearts and lungs of Lewis rats were removed and transplanted into the
abdomen of recipient rats by anastomosing the donor’s ascending aorta to the
recipient’s abdominal aorta. The transplanted hearts were maintained unloaded for
2 weeks in 49 animals. Eighteen transplanted hearts were removed after 2 weeks of
unloading. In 17 animals the donor’s right pulmonary artery was anastomosed to the
recipient’s abdominal aorta to reload the heart for an additional 2 weeks. In 14
animals the hearts were maintained unloaded for 4 weeks (an additional 2 weeks).
The unloaded and reloaded hearts were compared with normal rat hearts (n  18).
Results: In the unloaded hearts the left ventricular end-diastolic pressures remained
low. The left ventricular systolic pressures were lower than the aortic pressures. The
left ventricular weights (n  8) and volumes (n  4) remained significantly lower
(P  .01) than in the normal hearts. Two weeks after reloading, the left ventricular
end-diastolic pressure (n 8) increased (P .01), and the ventricle ejected. The left
ventricular systolic pressures exceeded the aortic pressures. The left ventricular
weights and volumes increased (P  .01) and approached those of normal hearts.
Matrix metalloproteinase 9 (n  6/group) levels decreased in the unloaded state
(P  .02) and increased back to normal values after reloading.
Conclusions: This surgical model simulated left ventricular assist device unloading
of the left ventricle. The second operation reloaded the left ventricle, which then
enlarged. This model will permit the evaluation of adjunctive interventions, such as
cell transplantation, intended to facilitate successful left ventricular assist device
removal and prevent recurrent dilatation.
Left ventricular assist devices (LVADs) are an effective treatment for patientswith severely decompensated heart failure. As a bridge to transplantation,LVAD treatment permits recovery from heart failure and improves quality of
life.1,2 LVAD support is accompanied by marked hemodynamic, neurohumoral,
physiologic, cellular, and molecular changes of myocardial recovery.3-9 However,
the use of an LVAD as a bridge to recovery remains controversial.10,11 Hetzer and
colleagues12 reported that 13 of 23 patients were successfully weaned from LVADs.
Six of them remained free of subsequent cardiac failure after removal of the LVAD,
but 7 patients had recurrent cardiac failure. Mancini and associates13 were unable to
reproduce Dr Hetzer’s experience. This group found that recurrent cardiac dilatation
and worsening heart failure developed after LVAD removal.14 Although some
patients have been successfully weaned from LVAD support, the process is unpre-
dictable, and adjunctive therapies might be required to permit successful LVAD
removal.15
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and dysfunction in models of progressive cardiomyopathy.16,17
Cell transplantation during LVAD therapy might prevent re-
current cardiac deterioration after LVAD removal. The poten-
tial benefits of cell transplantation or any other therapy to
prevent recurrent ventricular dysfunction after LVAD removal
have not been evaluated either in patients or in animal models.
Therefore, we developed an animal model to simulate LVAD
unloading followed by a period of reloading to simulate LVAD
removal. The rat heterotopic heart transplant model was first
Figure 1. Heterotopic heart transplantation. A, Unloading the
heart. The heart and lungs are transplanted into the abdomen of
the recipient. The ascending aorta of the donor is anastomosed to
the abdominal aorta of the recipient. B, Reloading the heart. The
right PA is anastomosed to the distal abdominal aorta of the
recipient. The gray arrows indicate coronary flow, the white
arrows indicate the blood flow from the abdominal aorta, and the
light gray dotted arrows indicate the mixed blood. Asc.Ao, As-
cending aorta; Abd.Ao, abdominal aorta; PV, Pulmonary vein; RA,
right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle;
CS, coronary sinus; rt, right; lt, left.reported in the 1960s.18,19 In the first model the hearts were
100 The Journal of Thoracic and Cardiovascular Surgery ● Julyunloaded, and therefore the model did not reflect the clinical
situation. The surgical approaches were modified in the 1990s
to permit cardiac loading.20-24 We further modified the surgical
approaches to permit the heterotopic heart to be unloaded and
then reloaded to simulate LVAD removal. This model will
help to determine whether adjunctive therapy, such as cell
transplantation, will prevent or delay recurrent cardiac failure
after LVAD removal.
Methods
All experimental procedures were approved by the Animal Care
Committee of the University Health Network. The studies were per-
formed according to the guidelines in the “Guide to the Care and Use
of Experimental Animals” (National Institutes of Health publication
no. 85-23, revised 1985). Male Lewis inbred rats weighting 290 to
320 g (Charles River Canada Inc, Quebec, Canada) were used as
donors, and those weighting 290 to 350 g were used as recipients.
Outline of the Surgical Model
The heart and lungs of the donor rat were transplanted heterotopically
into the abdomen of the recipient rat. The ascending aorta of the donor
heart was anastomosed to the abdominal aorta of the recipient. The
transplanted heart was unloaded after transplantation, and only the
coronary venous blood entered the left ventricle (LV) through the
coronary sinus, the right atrium, the right ventricle, the pulmonary
artery (PA), the lungs, the pulmonary veins, and the left atrium
(Figure 1, A). Two weeks later, the transplanted heart was reloaded by
anastomosing the right PA to the distal abdominal aorta. Saturated
blood entered the LV of the donor heart through the right lung, the
pulmonary vein, and the left atrium (Figure 1, B). The heart pumped
out the blood, which accumulated in the LV from both the coronary
sinus and the PA into the abdominal aorta. An outline of the exper-
imental protocol is provided in Figure 2.
Heterotopic Heart-Lung Transplantation
The donor rats were anesthetized by means of an intraperitoneal
injection of ketamine (50 mg/kg of body weight) and pentobarbital
sodium (50 mg/kg of body weight). The animals were intubated and
ventilated with a Harvard ventilator (respiration rate, 60 breaths/min;
tidal volume, 3 mL). The heart and lungs were exposed through a
median sternotomy. Both the right and left superior venae cavae and
the inferior vena cava (IVC) were taped. The mediastinal lobe of the
right lung was resected. The left diaphragm was incised posteriorly
near the aorta to provide a long segment of the thoracoabdominal
aorta, and 2 sections were isolated with tapes.
Before the heart and lungs were harvested, the recipient rat was
anesthetized with the inhalation of isoflurane (1.5%) and ventilated
as described above. After the abdomen was opened through a
midline incision, the intestines were pushed to the right side and
were kept moist during the operation.
After an injection of 300 U of heparin sodium into the donor’s
IVC, the distal thoracoabdominal aorta was ligated, a 20-gauge
needle was inserted upward into the thoracic aorta, and 20 mL of
cardioplegia (cold saline with 20 mEq/L of potassium chloride)
was injected into the heart through the thoracic aorta. The IVC and
both the right and left superior venae cavae were ligated and
divided. Then the ascending aorta and the trachea were transected,
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Pand the heart and lungs were excised and transferred into a con-
tainer containing a cold cardioplegic solution until transplantation.
The recipient’s abdominal aorta was clamped, and a 3-mm longi-
tudinal incision was made in the aorta to which the donor’s ascending
aorta was anastomosed with 7-0 polypropylene sutures. The donor
heart (n 49) was kept cold with wet gauze during the anastomosis.
Before the suture was tied, air was removed from the donor’s heart
and ascending aorta, and the clamps were released. After the heart
started beating, the right PA was dissected and wrapped in preparation
for the second operation. Sepra film (Genzyme, Tokyo, Japan) was
placed around the anastomosis to reduce adhesions. The abdomen was
closed with 3-0 absorbable sutures.
Reloading the LV of the Donor Heart (Second
Operation)
Two weeks after heart-lung transplantation, the rat was anesthetized
with inhalation of isoflurane, as described above, and the abdomen
was opened. The abdominal aorta just distal to the previous anasto-
mosis was dissected. The wrapped right PA of the donor was exposed
and ligated proximally. The distal PA was clamped, and the right PA
was divided just distal to the ligature. The abdominal aorta was
clamped, and a 2-mm incision was created. The distal end of the right
PA was anastomosed to the incision in the abdominal aorta with a
continuous 8-0 suture. The clamps were released after the anastomosis
was completed. The right lung turned red as soon as the clamps were
released. The abdomen was closed with continuous 3-0 absorbable
sutures.
Measurement of Donor’s Left Ventricular Pressure,
Recipient’s Aortic Pressure, Left Ventricular Weight,
and Left Ventricular Volume
The donor’s left ventricular pressure, the recipient’s aortic pres-
sure, the left ventricular weight, and the left ventricular volume
were measured at 4 different times after the operation (Figure 2).
Figure 2. In this study 49 heart and lung transplantat
performed on 17 transplanted hearts (RL). Eighteen trans
(UL2). Fourteen transplanted hearts were kept unloade
were also evaluated. Six hearts from each group wer
for left ventricular pressure and volume analysis. W&Twelve hearts were evaluated 2 weeks after unloading (UL2), and
The Journal of Thoraci8 hearts remained in the unloaded state and were evaluated 4
weeks after transplantation (UL4). Two weeks after transplanta-
tion, 17 hearts underwent reoperation, and the LV was reloaded,
and 2 weeks later (4 weeks after transplantation), the reloaded
hearts were evaluated (RL, n  7). Left ventricular weights and
volumes of 12 normal hearts were also evaluated. Six hearts from
each group were used for matrix metalloproteinase (MMP) anal-
ysis, which were not used for left ventricular pressure and volume
analysis.
After achievement of general anesthesia, the transplanted heart
was exposed. A 22-gauge angiocath was inserted into the LV
through the apex, and the catheter was connected to a pressure
transducer (model p10EZ; Viggo-Spectramed, Oxnard, Calif) and
a differentiator amplifier (model 11-G4113-01; Gould Instrument
System Inc, Valley View, Ohio). The pressures were recorded with
a computer. The left ventricular end-diastolic pressure (LVEDP)
and the heart rate for 5 seconds were recorded and averaged with
the computer software Ponemah Physiology program (Gould In-
strument Systems, Inc). After the left ventricular pressure was
recorded, the tip of the catheter was moved into the aorta, and the
aortic pressure was recorded (n  8/group).
After measuring the pressures, the hearts were removed and
immediately put into cold saline. The right ventricles were re-
moved carefully, and the left ventricular weight was measured
(n  6-8 in each group). For morphologic studies, the transplanted
hearts were arrested with 10 mL of cardioplegic solution and fixed
with formalin at a pressure of 30 mm Hg (n  4 in each group).
The LV was cut into 2-mm-thick slices, and the left ventricular
volume was calculated by means of planimetry.
Quantification of MMP-9
Six hearts in each group were also quickly excised and arrested in
ice-cold phosphate-buffered saline. The anterior free walls of the
hearts were snap-frozen in liquid nitrogen and stored at80°C for
were performed in total. The second operation was
ted hearts were removed 2 weeks after transplantation
a total of 4 weeks (UL4). Eighteen normal hearts (Nor)
d for MMP analysis, and these hearts were not used
eight and pressure; LVV, left ventricular volume.ions
plan
d for
e use
P, Wenzyme activity. The relative abundance of MMP-9 in left ven-
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blotting procedures, as described previously.25
Data Analysis
All results were presented as means  SD. Comparisons between
groups were performed by means of analysis of variance, and
when the F ratio was statistically significant, differences were
specified by using the Tukey multiple range test.
Results
Forty-nine heart-lung transplantations were performed in
total. The average time for heart-lung transplantation was
73.6  6.1 minutes. The operative time for the recipients
was 53.7  5.2 minutes. The ischemic time (from injection
of cardioplegia to declamping) was 22.7  1.7 minutes, the
clamp time was 17.6  1.6 minutes, and the time for the
anastomosis was 13.4  1.3 minutes. All hearts started
beating immediately after declamping. After several prac-
Figure 3. The pressure traces of the donor LV and the r
heart (A) is lower than the recipients’ aortic pressure
aortic pressure is changed by the level of anesthesia, t
left ventricular pressure is always lower than the recip
the left ventricular pressure is always higher than the
is clamped, the LVEDP slowly decreases. When the P
systolic pressure slowly increase. AP, Aortic pressure
arrows, the left ventricular pressure; rt, right.tice procedures, all rats survived heart-lung transplantation.
102 The Journal of Thoracic and Cardiovascular Surgery ● JulySeventeen animals underwent operations at 2 weeks after
heart-lung transplantation for reloading. The average oper-
ating time for the second operation was 77.4 7.4 minutes.
Adhesions were found around the right PA and the abdom-
inal aorta, despite the use of Sepra film. The clamp time for
the second operation was relatively long (24.3  2.4 min-
utes), but there was no ischemic time to the transplanted
hearts because the aorta was clamped distal to the previous
anastomosis. After declamping, the right lung became per-
fused with arterial blood, and the color immediately turned
red. Two weeks after the second operation, the right lung
was still bright red in all animals.
Figure 3 shows representative examples of the pressure
traces in the unloaded and loaded ventricles. The left ven-
tricular systolic pressures (90  7 mm Hg) were consis-
tently lower than the recipients’ aortic pressure (98 6 mm
Hg) in the unloaded state. After reloading the ventricle, the
ent aorta. The left ventricular pressure in the unloaded
but higher in the reloaded heart (B and B’). When the
ndency remains consistent. In the unloaded heart, the
’s aortic pressure (C and C’), and in the reloaded heart
pressure (D and D’). When the right pulmonary artery
then unclamped, both LVEDP and the left ventricular
left ventricle; black arrows, the aortic pressure; whiteecipi
(A’)
his te
ient
aortic
A is
; LV,systolic ventricular pressures (91  7 mm Hg) were inter-
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Pmittently greater than the recipient aortic pressure (89  8
mm Hg), resulting in intermittent ventricular ejection.
The LVEDP of the hearts before transplantation into the
Figure 3.abdomen varied between 2 and 8 mm Hg, depending on the
The Journal of Thoracianesthetic level, the extent of the bleeding from the sternot-
omy, and whether the pleura was opened. After 2 weeks in
the unloaded state (UL2), LVEDP was 4.3  1.1 mm Hg
tinued.Con(Figure 4). After an additional 2 weeks in the unloaded state
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different from the LVEDP at 2 weeks (UL2). After the
hearts were reloaded (RL) for 2 weeks, the LVEDP was
12.4  3.7 mm Hg, which was significantly higher than the
LVEDP in the unloaded state at 2 weeks (UL2, P  .01) or
4 weeks (UL4, P  .01). Heart rates in groups UL2, UL4,
and RL were 253  39, 263  29, and 252  39 beats/min,
respectively. There were no statistical differences among
the 3 groups.
Figure 5, A, depicts the transplanted hearts during the
experiment. Normal left ventricular weight was 561  31
mg (Figure 5, B). At 2 weeks in the unloaded state (UL2),
the left ventricular weight decreased to 312  22 mg (P 
.01). When the hearts remained unloaded for 2 more weeks
(UL4), the low weight was maintained (301  22 mg, P 
.32). When the hearts were reloaded for 2 weeks (RL), the
left ventricular weight increased (562  67 mg), which was
significantly greater than that of UL2 and UL4 (P .01 and
P  .01, respectively) and not different from that of the
normal LV (P  .41).
The left ventricular volume of the normal heart was 0.32
 0.02 mL (Figure 5, C). After 2 weeks of unloading
(UL2), the left ventricular volume decreased significantly to
0.16  0.01 mL (P  .001). After 2 weeks of reloading
(RL), the left ventricular volume enlarged again to 0.28 
0.05 mL (P .004 compared with group U2), which was as
similar to that seen in normal hearts (P  .20).
MMP-9 levels in the myocardium decreased after 2
weeks of unloading (UL2, P .05) and remained low when
the hearts were kept unloaded longer (UL4, P  .01)
Figure 4. LVEDP. After the second operation (RL), the LVEDP
increased significantly compared with the LVEDP of the unloaded
hearts 2 weeks (UL2) and 4 weeks (UL4) after heart-lung trans-
plantation. *P < .05 compared with UL2.compared with that seen in the normal hearts (Figure 6).
104 The Journal of Thoracic and Cardiovascular Surgery ● JulyHowever, the MMP-9 level increased (P  .025) when the
unloaded hearts were reloaded compared with that in the
UL4 group.
Discussion
LVADs have been used extensively as a bridge to trans-
plantation, and they have been proposed for use as destina-
tion therapy. Eventually, the devices might be used as a
bridge to recovery. However, the initial experience with this
process has been disappointing. A variety of interventions,
such as cell transplantation, have been proposed to treat the
unloaded heart receiving LVAD assistance to prevent re-
current failure after LVAD removal. None of these inter-
ventions have been adequately tested because an animal
Figure 5. A, Photographs of the normal heart (Nor), the unloaded
heart (UL2), and the reloaded heart (RL). After unloading, the heart
becomes smaller than the normal heart. After reloading, the heart
dilates. B, The weight of the LVs decreased significantly 2 weeks
after the heart-lung transplantation (UL2) but increased 2 weeks
after reloading (RL). C, The left ventricular volume significantly
decreased compared with that of the normal heart after unloading
(UL2), but 2 weeks after reloading (RL), the left ventricular volume
increased again. *P < .05 compared with the left ventricular
volume of the normal heart.model of left ventricular unloading followed by left ven-
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Ptricular reloading has not been described. Therefore, we
developed this surgical model, which will permit the testing
of alternate strategies to prevent recurrent cardiac failure
after reloading.
This new heterotopic heart transplantation model ade-
quately unloaded and then reloaded the heart. We evaluated
the hearts after 2 weeks in the unloaded condition and again
after 2 weeks in the reloaded state. However, the time
course could be altered as long as the physiologic conditions
of the implanted organs are maintained. A longer duration in
the unloaded state might be required for normalization of
ischemically injured hearts. A longer duration after reload-
ing might also be required to determine the fate of inter-
ventions, such as cell transplantation.
The small ventricular volumes and low weights after
unloading for 2 weeks demonstrated the adequacy of ven-
tricular unloading.26 After the first operation, only the cor-
onary blood flow entered the LV, and this blood was even-
tually ejected, despite the low left ventricular systolic
pressure. After the second operation, a large volume of
saturated blood continuously entered the LV from the ab-
dominal aorta (in addition to the coronary venous blood)
and was ejected into the abdominal aorta. After transplan-
tation, the hearts were unloaded with low pressures and
volumes. After the second operation, the heart was reloaded,
and both pressures and volumes returned to the pretrans-
plantation values. Therefore, this model simulates the con-
ditions present when cardiomyopathic hearts are unloaded
by means of LVAD support and reloaded by means of
LVAD removal.
At the first operation, the single anastomosis reduced the
ischemic time compared with the time required for conven-
tional heterotopic rat heart transplantation. The short isch-
emic time and short clamp time might have contributed to
the low mortality and morbidity we experienced. A limita-
tion of the present study is that we did not include decom-
pensated hearts, such as drug-induced or ischemic cardio-
myopathic rat hearts. The short ischemic time required for
heart transplantation might permit the implantation of de-
compensated hearts, which will determine the clinical rele-
vance of this model. The second operation was accom-
plished without ischemic heart damage, but adhesions
provided a technical challenge. The bioabsorbable sheet
might have reduced but did not prevent adhesion formation,
especially around the PA and trachea. To facilitate the
second operation, we wrapped the right PA to protect it
from even more dense adhesion formation. The wrap helped
to identify and dissect the right PA at the second operation.
The volume of the blood, which flowed into the transplanted
heart from the abdominal aorta after the second operation,
was not estimated in our experiment. The anastomosis be-
tween the PA and the abdominal aorta was 2 mm in diam-
eter and larger than the diameter of the abdominal aorta.
The Journal of ThoraciTherefore the blood flow into the transplanted heart was
only limited by the pulmonary vascular resistance.
We found that both the size and weight of the implanted
hearts decreased after unloading and enlarged again after
reloading. The changes in size and weight were probably the
result of unloading and reloading. The changes were un-
likely to have been caused by myocardial ischemia because
the ischemic time was shorter than those reported previous-
ly.20-24 A similar response was described in patients after
LVAD therapy, with left ventricular dilation and cardiac
failure often recurring after LVAD removal. The functional
recovery was frequently only temporary. The injured myo-
cardium did not maintain its architecture but dilates, and
heart failure recurs after the removal of LVAD support.
Because the normal heart was used in this study, the regres-
sion of ventricular weight was not necessarily beneficial.
Future research is required to study the effect of ventricular
unloading on hearts with a dilated cardiomyopathy. This
model will help us to understand the process of reestablish-
ing normal function in cardiomyopathic hearts, to under-
stand the mechanisms of reverse remodeling during LVAD
therapy, and to determine whether new therapies, such as
cell transplantation, can prevent recurrent dilation and car-
Figure 6. The changes in MMP-9 levels are depicted during the
study. Two weeks after the heart transplantation (2 weeks of
unloading), MMP-9 levels significantly decreased compared with
those of the normal hearts and stayed low, whereas the hearts
were kept unloaded for the additional 2 weeks. After the hearts
were reloaded, MMP-9 levels increased again. *P < .05 com-
pared with the normal hearts. Nor, The group of normal hearts;
UL2, the hearts after 2 weeks of unloading; RL, the hearts re-
loaded for 2 weeks after 2-week unloading; UL4, the hearts
unloaded for 4 weeks.diac failure after LVAD removal.
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before and after unloading and reloading. We found that
unloading decreased MMP-9 levels, which remained low as
long as the hearts were unloaded. The same phenomena has
been reported after LVAD support in patients with cardio-
myopathic hearts.7 Other groups described changes in gene
expression and calcium flux after cardiac unloading,27-29 but
no information has been reported on gene expression or
molecular alterations after LVAD removal. In this surgical
model, MMP-9 levels increased to normal values when the
hearts were reloaded. The increased MMP levels might
contribute to the recurrence of heart failure after LVAD
removal.
In conclusion, this new heterotopic rat heart transplanta-
tion model can provide both a nonworking heart model and
a working heart model after a variable period of unloading.
Therefore the model will simulate the conditions of LVAD
support for the failing heart and cardiac recovery after
removal of an LVAD.
We thank Professor Tohru Sakamoto, Department of Thoracic
Organ Replacement, Graduate School of Medicine, Tokyo Medi-
cal and Dental University, for technical advice.
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